Kara Elam,  —

Do NOX enzymes play a pivotal role in idiopathic pulmonary fibrosis (IPF)? This is the question researchers hope to answer with a newly funded research program evaluating the role of NOX enzymes. Genkyotex, a company focused on developing therapies for chronic diseases, recently announced that the U.S. National Institutes of…

New York scientists have created a mini-lung in a laboratory that mimics a real lung’s response to a viral infection in pulmonary fibrosis. The mini-lung, which scientists call an organoid, will increase understanding of lung diseases,  leading to better treatments, the researchers said. Dr. Hans-Willem Snoeck, a professor at Columbia University…

Left to right, Chicago Mayor Rahm Emanuel; Bill Vick, PF Warriors; Teresa Barnes, patient advocate; Tom Hurvis, Three Lakes Partners; Steven Collens, MATTER; and Ken Bahk, Three Lakes Partners. Photo Credit: Sean Su | CloudSpotter A group of philanthropists, medical-tech and business people have issued…

New York City-based Kadmon Corp., a biopharma focused on developing therapies for significant unmet medical needs, recently announced the start of the first dosing regimen in a patient in its Phase 2 clinical trial assessing the drug KD025, the company’s rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, for the treatment of idiopathic pulmonary fibrosis…

Belgian based biotech firm Galapagos, a company that specializes in the discovery and development of molecular medicines with new drug targets, announced that its seven year proprietary investment agreement with Janssen Pharmaceuticals, part of the Johnson & Johnson healthcare brand, has been terminated by mutual agreement between the two…

A study published this week in The Journal of Molecular Medicine Reports  discussed the discovery of biological mechanisms that may have important implications in the future treatment of idiopathic pulmonary fibrosis (IPF). The research was conducted by an international team of collaborating scientists from the University…